title: Fragment informatics and computational fragment-based drug design: an overview and update.
abstract: Fragment-based drug design (FBDD) is a promising approach for the discovery and optimization of lead compounds. Despite its successes, FBDD also faces some internal limitations and challenges. FBDD requires a high quality of target protein and good solubility of fragments. Biophysical techniques for fragment screening necessitate expensive detection equipment and the strategies for evolving fragment hits to leads remain to be improved. Regardless, FBDD is necessary for investigating larger chemical space and can be applied to challenging biological targets. In this scenario, cheminformatics and computational chemistry can be used as alternative approaches that can significantly improve the efficiency and success rate of lead discovery and optimization. Cheminformatics and computational tools assist FBDD in a very flexible manner. Computational FBDD can be used independently or in parallel with experimental FBDD for efficiently generating and optimizing leads. Computational FBDD can also be integrated into each step of experimental FBDD and help to play a synergistic role by maximizing its performance. This review will provide critical analysis of the complementarity between computational and experimental FBDD and highlight recent advances in new algorithms and successful examples of their applications. In particular, fragment-based cheminformatics tools, high-throughput fragment docking, and fragment-based de novo drug design will provide the focus of this review. We will also discuss the advantages and limitations of different methods and the trends in new developments that should inspire future research.
authors.affiliation: Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai, 200433, People's Republic of China. shengcq@hotmail.com
authors.forename: Chunquan
authors.initials: C
authors.lastname: Sheng
authors.forename: Wannian
authors.initials: W
authors.lastname: Zhang
mesh_terms: D058888:14-alpha Demethylase Inhibitors / Q000138:chemical synthesis; D020134:Catalytic Domain; D019295:Computational Biology / Q000379:methods*; D021984:Cyclophilin A / Q000037:antagonists & inhibitors; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods; D008024:Ligands; D062105:Molecular Docking Simulation; D052248:Nitric Oxide Synthase Type I / Q000037:antagonists & inhibitors; D011955:Receptors, Drug / Q000737:chemistry; D058829:Serotonin 5-HT1 Receptor Antagonists / Q000138:chemical synthesis; D012984:Software; D013329:Structure-Activity Relationship
chemical_list: D058888:14-alpha Demethylase Inhibitors; D008024:Ligands; D011955:Receptors, Drug; D058829:Serotonin 5-HT1 Receptor Antagonists; D052248:Nitric Oxide Synthase Type I; D021984:Cyclophilin A